Showing results (291-300 of 6,708) with videos related to

Sort By:
Pageof 671
Oncotargets and Therapy|July 23, 2016
Superiority of helical tomotherapy on liver sparing and dose escalation in hepatocellular carcinoma: a comparison study of three-dimensional conformal radiotherapy and intensity-modulated radiotherapyQianqian Zhao, Renben Wang, Jian Zhu, et al.
Oncotargets and Therapy|July 23, 2016
Clinicopathological significance of p15 promoter hypermethylation in multiple myeloma: a meta-analysisBing Wei, Shuhua Yang, Bo Zhang, et al.
Oncotargets and Therapy|July 23, 2016
Chromatin assembly factor 1, subunit A (P150) facilitates cell proliferation in human hepatocellular carcinomaMeng Xu, Yuli Jia, Zhikui Liu, et al.
Oncotargets and Therapy|July 23, 2016
LncRNA GAS5 is a critical regulator of metastasis phenotype of melanoma cells and inhibits tumor growth in vivoLong Chen, Huixin Yang, Yanbin Xiao, et al.
Oncotargets and Therapy|May 20, 2021
Identification of the EMT-Related Genes Signature for Predicting Occurrence and Progression in Thyroid CancerQiang Li, Sheng Jiang, Tienan Feng, et al.
Oncotargets and Therapy|May 21, 2021
Regional Brain Glucose Metabolism and Its Prognostic Value in Pretreatment Extranodal Natural Killer/T-Cell Lymphoma PatientsZiwei Zhou, Zhe Guo, Qingqiao Hu, et al.
Oncotargets and Therapy|May 12, 2021
Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 InhibitorsChao Li, Xujun Li
Oncotargets and Therapy|May 13, 2021
Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From "All-Comers" to "Personalized" ApproachKenichi Harada, Masaki Shiota, Akinori Minato, et al.
Oncotargets and Therapy|May 13, 2021
Increased Collagen Type V α2 (COL5A2) in Colorectal Cancer is Associated with Poor Prognosis and Tumor ProgressionJie Wang, Ying-Hua Jiang, Peng-Yuan Yang, et al.
Oncotargets and Therapy|May 17, 2021
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid MalignanciesSarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
Pageof 671